~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial...
Hence then, the article about pathalys pharma presents positive data from pivotal phase 3 studies of upacicalcet in featured oral presentation at asn kidney week 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026 )
Also on site :
- Ageless Jane Seymour Takes Halloween Inspiration From 2 Iconic Roles—Dr. Quinn and ‘James Bond’s’ Solitaire
- A duck farmer’s five-story house stood alone in a Chinese highway for over a year; it came down in 2012 for 260,000 yuan
- Peace talks, Zelensky, the EU, ‘political schizophrenia’ and a new Cold War: RT stories that shaped the week